Eliem Therapeutics Inc. (ELYM)
Eliem Therapeutics Statistics
Share Statistics
Eliem Therapeutics has 67.06M shares outstanding. The number of shares has increased by 125.4% in one year.
| Shares Outstanding | 67.06M |
| Shares Change (YoY) | 125.4% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 26.24M |
| Failed to Deliver (FTD) Shares | 48.97K |
| FTD / Avg. Volume | 9.42% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2.07 and the forward PE ratio is null. Eliem Therapeutics's PEG ratio is 0.08.
| PE Ratio | -2.07 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.68 |
| P/FCF Ratio | -3.54 |
| PEG Ratio | 0.08 |
Enterprise Valuation
Eliem Therapeutics has an Enterprise Value (EV) of -19.9M.
| EV / Sales | 0 |
| EV / EBITDA | 1.46 |
| EV / EBIT | 0.97 |
| EV / FCF | 0.97 |
Financial Position
The company has a current ratio of 38.92, with a Debt / Equity ratio of 0.
| Current Ratio | 38.92 |
| Quick Ratio | 38.92 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -32.64% and Return on Invested Capital is -19.87%.
| Return on Equity | -32.64% |
| Return on Assets | -31.79% |
| Return on Invested Capital | -19.87% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.9M |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -21.47K |
| Effective Tax Rate | 0.06% |
Stock Price Statistics
The stock price has increased by 39.62% in the last 52 weeks. The beta is -0.38, so Eliem Therapeutics's price volatility has been lower than the market average.
| Beta | -0.38 |
| 52-Week Price Change | 39.62% |
| 50-Day Moving Average | 6.13 |
| 200-Day Moving Average | 5.58 |
| Relative Strength Index (RSI) | 25.78 |
| Average Volume (20 Days) | 519.72K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -21.47M |
| Net Income | -35.12M |
| EBITDA | -13.65M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.3 |
Balance Sheet
The company has 93.11M in cash and 349K in debt, giving a net cash position of 92.76M.
| Cash & Cash Equivalents | 93.11M |
| Total Debt | 349K |
| Net Cash | 92.76M |
| Retained Earnings | -155.98M |
| Total Assets | 226.02M |
| Working Capital | 222.26M |
Cash Flow
In the last 12 months, operating cash flow was -20.6M and capital expenditures 0, giving a free cash flow of -20.6M.
| Operating Cash Flow | -20.6M |
| Capital Expenditures | 0 |
| Free Cash Flow | -20.6M |
| FCF Per Share | -0.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELYM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -48.2% |
| FCF Yield | -28.27% |
Analyst Forecast
Currently there are no analyst rating for ELYM.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 53.65 |
| Piotroski F-Score | 4 |